Full-Time

Quality Assurance Associate

Pharmaceutical Manufacturing

Granules

Granules

501-1,000 employees

Vertically integrated API and dosage manufacturer

Compensation Overview

$55k - $65k/yr

Manassas, VA, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Quality Assurance (QA)
Version Control
Data Analysis

Get referred to Granules

See people who can refer or advise you

Requirements
  • Knowledge of current good manufacturing practices (cGMP) compliance within the pharmaceutical manufacturing industry.
  • Experience writing and maintaining cGMP documentation.
  • Ability to analyze data and information and resolve complex issues.
  • Verbal and written communication skills.
  • Ability to work and communicate with cross-functional teams.
  • Ability to manage multiple priorities and reprioritize tasks.
  • At least two years of experience in a quality assurance role in a cGMP-regulated environment.
  • A college degree, preferably in a science such as Pharmacy, Biology, or Chemistry.
  • Ability to stand, sit, talk, hear, and use hands and fingers to operate computer and telephone keyboards.
  • Close vision sufficient for computer work.
  • Ability to sit at a computer terminal for an extended period.
  • Ability to lift 10 to 15 pounds.
  • Ability to work in a confined area.
Responsibilities
  • Manage and maintain company document control and archival systems, including hardcopy and electronic records, in compliance with internal procedures, policies, and regulatory requirements.
  • Manage the routing, review, approval, distribution, and archival of new and revised controlled documents.
  • Track controlled documents using document control numbers, logbooks, change requests, and document status reports.
  • Archive and maintain hardcopy and electronic copies of batch record files, audit files, vendor files, product and label files, and change history files.
  • Control and issue labeling components.
  • Manage document control logbooks and spreadsheets.
  • Release finished product batches that have been packaged.
  • Provide new-hire training on good manufacturing practices, safety, and pharmacovigilance, and maintain the training program documentation.
  • Ensure standard operating procedures are periodically reviewed for relevance and accuracy in compliance with company policies and procedures.
  • Collaborate with team members to ensure timely documentation deliverables.
  • Ensure all documents are current with respect to version control and issuance.
  • Perform and support maintenance and closure activities for reports, protocols, exceptions or deviations, corrective and preventive actions (CAPAs), change controls, and complaints.
  • Maintain current good manufacturing practices compliance in document control.
  • Perform other activities assigned by the supervisor.

Granules India makes APIs, PFIs, and finished dosages, using large-scale, vertically integrated plants that control production from base chemicals to final medicines. Its products include common off-patent APIs like Paracetamol, Ibuprofen, Metformin, and Guaifenesin, and it is expanding into more complex areas such as MUPS, oncology, and peptide therapies with US FDA approvals. The company differentiates itself through full vertical integration, large scale, and a global manufacturing footprint that supports both contract manufacturing and its own branded products, offering supply security and cost competitiveness. Its goal is to deliver reliable, affordable medicines to customers worldwide while growing capabilities in complex therapies and pursuing sustainable practices like green chemistry.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

2014

Get referred to Granules

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q3 FY26 revenue rose 22% to INR 1,388 crores, led by North America and Europe.
  • July 2026 inspections at Genome Valley and Chantilly improved regulatory optionality and capacity.
  • Europe grew 151% year-on-year in FY26, while peptide CDMO opened a new revenue vertical.

What critics are saying

  • FDA warning letter dated February 26, 2025 threatens Gagillapur product approvals until remediation closes.
  • Reuters on April 9, 2026 reported record-keeping and contamination concerns still burden management.
  • Any second FDA action at Gagillapur can shut U.S. launches and damage Granules' generics franchise.

What makes Granules unique

  • Granules integrates APIs, PFIs, and dosages, preserving cost control across the value chain.
  • February 2025 Senn Chemicals acquisition adds peptide CDMO capabilities and European regulated-market access.
  • Granules shipped in 80 countries and won 94 approvals by August 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours